Amgen to buy Horizon Therapeutics for $26.4B
December 12, 2022 at 10:38 AM EST
Amgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company’s medical legacy. Horizon's best-selling drug is Tepezza.
